氯苯唑酸与ATTR心脏淀粉样变性患者健康状态的相关性:ATTR-ACT随机临床试验的事后分析
该研究为ATTR-ACT随机对照试验的事后分析,纳入441例转甲状腺素蛋白(ATTR)心脏淀粉样变性且基线NYHA I-III级症状的患者,比较氯苯唑酸(80mg或20mg合并队列)与安慰剂对健康状态的影响。结果显示氯苯唑酸组KCCQ-OS评分改善的比值比为2.4(95%CI 1.6-3.4,P<.001),在NYHA III级患者中同样观察到健康状态改善更常见、下降更少见。
要点
- 氯苯唑酸显著改善ATTR心脏淀粉样变性患者的KCCQ-OS健康状态评分。
- NYHA III级患者中,氯苯唑酸组30个月时健康状态改善更常见(35% vs 10%)。
- 氯苯唑酸组30个月时存活且未恶化的患者比例更高(37% vs 15%)。
核心结论
- 在ATTR-ACT试验中,尽管基线NYHA III级症状患者总体结局较差,但氯苯唑酸治疗相比安慰剂仍带来更好的健康状态。
研究设计与样本
- ATTR-ACT随机临床试验的事后分析,纳入441例ATTR心脏淀粉样变性且基线NYHA I-III级症状的患者(氯苯唑酸264例,安慰剂177例),来自13个国家48个中心。
- 干预为氯苯唑酸葡甲胺80mg或20mg(合并队列)对比安慰剂。
- 采用堪萨斯城心肌病问卷总体摘要(KCCQ-OS)既定阈值定义应答组。
主要发现
- 患者平均(SD)年龄74.3(7.0)岁,男性398例(90%),女性43例(10%)。
- 基线KCCQ-OS平均(SD)评分:氯苯唑酸组67.3(21.4),安慰剂组65.9(21.7)(范围0-100,100为最佳健康)。
- 氯苯唑酸组KCCQ-OS评分显著向更好方向偏移(10分改善的比值比2.4;95%CI 1.6-3.4;P<.001)。
- 氯苯唑酸组更多患者在所有时间点存活且未恶化(30个月时37% vs 15%)。
- 在30个月时存活的NYHA III级患者中,氯苯唑酸组相比安慰剂健康状态改善更常见(35% vs 10%),下降更少见(38% vs 57%)。
临床怎么用
- 对于ATTR心脏淀粉样变性患者,包括NYHA III级症状者,氯苯唑酸治疗可改善健康状态并减少恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations and minimized patient-reported health status deterioration at 30 months in patients with transthyretin (ATTR) amyloidosis. However, the clinical significance of health status changes remains unclear, particularly in patients with New York Heart Association (NYHA) class III symptoms who experienced more cardiovascular-related hospitalizations than those with NYHA class I-II symptoms. OBJECTIVE: To evaluate the health status of patients taking tafamidis with baseline NYHA class III symptoms. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial post hoc analysis evaluated data for patients with transthyretin (ATTR) cardiac amyloidosis and NYHA class I-III symptoms at baseline who were enrolled in ATTR-ACT, a placebo-controlled study of tafamidis held at 48 sites in 13 countries. INTERVENTIONS: Tafamidis meglumine, 80 mg or 20 mg (pooled cohort), vs placebo. MAIN OUTCOMES AND MEASURES: Established thresholds for clinical benefit on the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) were used to define response groups (very large decline to very large improvement); the proportion of patients in each group was calculated within each baseline NYHA class. RESULTS: Among 441 patients (264 tafamidis, 177 placebo), the mean (SD) age was 74.3 (7.0) years; 398 (90%) were male and 43 (10%) were female. Mean (SD) baseline KCCQ-OS scores were 67.3 (21.4) in the tafamidis group and 65.9 (21.7) in the placebo group (range: 0-100, with 100 indicating the best health). There was a significant shift toward better KCCQ-OS scores in patients receiving tafamidis (odds ratio for 10-point improvement 2.4; 95% CI, 1.6-3.4; P < .001). More patients taking tafamidis were alive and not worse at all time points (37% vs 15% at month 30). These findings were similar in patients with NYHA class III symptoms. In patients with NYHA class III symptoms alive at 30 months, improvements in health status were more common (35% vs 10%) and declines were less common (38% vs 57%) with tafamidis vs placebo. CONCLUSIONS AND RELEVANCE: In ATTR-ACT, although patients with baseline NYHA class III symptoms had worse overall outcomes, treatment with tafamidis yielded better health status compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01994889.
引用
- Sperry BW, Hanna M, Maurer MS, et al. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 36723935. doi:10.1001/jamacardio.2022.5251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。